Technology appraisal TA217 Alzheimer's disease – donepezil, galantamine, rivastigmine and memantine

Technology appraisal TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantineThis guidance replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).

Donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and memantine is now recommended as an option for managing moderate Alzheimer’s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer’s disease.

Download: http://www.nice.org.uk/nicemedia/live/13419/53619/53619.pdf